close search

ACE2 inhibitors for treatment of COVID-19

Inhibitors that prevent the interaction of the SARS-CoV-2 virus with the ACE2 receptor or prevent its internalisation may be candidate antiviral agents for COVID. We will screen ACE2 inhibitors for their ability to prevent viral entry and replication, examine their mechanisms of action and optimise the best candidates for formulation as an inhalant to treat patients with Acute Respiratory Distress Syndrome.

Our work aims to contribute to the development of an antiviral inhalant to treat patients with Acute Respiratory Distress Syndrome caused by SARS-CoV-2 infection (COVID).

We will screen ACE2 inhibitors for their ability to prevent cell entry and replication of SARS-CoV-2, examine their mechanism of action and optimise the best performing candidates for formulation as an inhalant to treat patients with Acute Respiratory Distress Syndrome.

Professor Heidi Drummer

Contact Professor Heidi Drummer for more information about this project.

EMAIL CALL

Partners +
Collaborators

  • Prof Robert Widdop (Monash University)
  • Prof Mibel Aguilar (Monash University)

Project
Team

Meet the project team. Together, we are translating research into better health, for all.